Barclays Maintains Overweight on Omada Health, Raises Price Target to $27
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and raises the price target from $25 to $27.
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and raises the price target from $25 to $27.